LENZ Therapeutics, Inc. LENZ

3.92 0.20 5.38% as of 25 Sep
Market cap
$117.4M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
0.00 — — — — — — —
P/S ratio
0.00 — — — — — — —
P/FCF ratio
0.00 — — — — — — —
P/Operating CF
(13.96) — — — — — — —
P/B ratio
1.62 — — — — — — —
Price to Tangible BV
1.62 — — — — — — —
EV/Sales
0.00 — — — — — — —
EV/EBITDA
0.00 — — — — — — —
EV/Operating CF
(2.49) — — — — — — —
EV/FCF
(2.46) — — — — — — —
Quick Ratio
13.81 20.10 3.55 20.57 31.04 0.62 0.00 —
Current Ratio
14.23 20.36 3.63 21.11 31.44 0.66 0.00 —
Net Debt/EBITDA
3.22 3.57 0.90 2.52 6.31 1.48 (75.83) —
Debt/Assets
0.00% 0.00% 0.00% 1.26% 0.00% 0.00% 36,750.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.01 0.00 0.00 (0.99) —
Asset Turnover
0.07 0.00 0.00 0.00 0.00 0.00 0.00 —
Operating CF/Net income
0.84 1.19 0.86 0.87 0.75 0.13 0.17 —
Capex/Depreciation
(2.88) (8.07) 0.03 (8.77) (7.82) (12.77) — —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(33.63%) (89.37%) (68.74%) (29.71%) (44.41%) 202.21% 0.32% —
ROA
(31.52%) (34.84%) (35.67%) (27.92%) (33.33%) (605.88%) (3,633.33%) —
ROIC
0.00% 0.00% 0.00% (205.64%) (534.02%) 0.00% 0.00% —
Return on Tangible Assets
(29.18%) (24.62%) (143.42%) (35.46%) (18.81%) 720.93% 4.91% —
Average Days of Receivables
6.29 — — — — — — —
Research and Development Expense of Revenue
97.81% 0.00% 0.00% 0.00% 0.00% 0.00% — —
Selling, General and Administrative Expense of Revenue
477.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
65.73% 0.00% 0.00% 0.00% 0.00% 0.00% — —
Graham Net Nets
0.61 — — — — — — —
Graham Number
0.00 — — — — — — —
Earnings Yield
(17.56%) — — — — — — —
Free Cash Flow Yield
(15.18%) — — — — — — —
Revenue per Share
0.66 0.00 0.00 0.00 0.00 0.00 0.00 —
Operating CF per Share
(2.40) (2.79) (30.82) (11.22) (12.79) (26.72) 0.00 —
Capex per Share
(0.03) (0.02) (0.02) (0.84) (1.39) (4.73) 0.00 —
Free Cash Flow per Share
(2.43) (2.81) (30.84) (12.06) (14.18) (31.45) 0.00 —
Cash per Share
10.15 9.83 33.59 34.21 91.22 60.71 0.00 —
Shareholders Equity per Share
9.87 9.59 (47.33) 37.79 92.93 (200.39) 0.00 —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
9.87 9.59 (47.33) 37.79 92.93 (200.39) 0.00 —
Free Cash Flow
(70.00) (59.86) (60.41) (94.57) (58.59) (10.27) (0.02) —
Working Capital
280.23 201.51 48.73 262.32 369.59 (10.94) (2.22) —
Capital Expenditures
(0.83) (0.47) (0.03) (6.59) (5.74) (1.54) — —
Net Current Asset Value
279.88 200.70 (95.84) 249.75 363.80 (66.87) (2.22) —
EV/EBIT
0.00 — — — — — — —
Capex to Sales
0.04 0.00 0.00 0.00 0.00 0.00 — —
Net Profit Margin
(430.25%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% —
Price to Operating Income
0.00 — — — — — — —
Other line items
Depreciation/Fixed assets
0.24 0.09 (19.30) 0.03 0.11 0.08 — —
Cash ROIC
(12.20%) (14.53%) 224.51% (19.45%) (7.80%) 22.33% 271.43% —
Accounts Receivable Turnover
0.00 — — — — — — —
Accounts Payable Turnover
0.10 0.00 0.00 3.30 0.48 0.08 — —
Inventory Turnover
0.00 — — 0.00 0.00 0.00 — —
Average Days of Payables
3,638.65 0.00 0.00 114.06 1,219.82 1,900.41 — —
Days of Inventory on Hand
2,563.73 — — 0.00 0.00 0.00 — —
Average Payables
4.21 4.98 4.16 2.53 1.54 1.54 — —
Average Assets
260.59 142.84 196.14 361.94 212.28 11.29 0.00 —
Average Common Equity
244.21 55.69 101.79 340.17 159.32 (33.81) (33.81) —

Fold the line items

Columns are period end dates